Sun Pharma’s subsidiary gets Health Canada approval for WINLEVI

20 Jun 2023 , 11:44 AM

Sun Pharma Canada Inc., a wholly-owned subsidiary of Sun Pharmaceutical Industries Limited, announced that WINLEVI (clascoterone cream 1%) has been approved by Health Canada.

WINLEVI has bagged Health Canada’s approval as the foremost and sole androgen receptor inhibitor for effectively treating acne vulgaris (acne) in individuals aged 12 and above. It is also the most recent formulation designed to address the hormonal aspect of acne for patients up to 40 years of age in Canada.

‘Due to hormonal triggers, acne is a common condition. Topical acne treatments for Canadians that target the hormonal cascade of acne have been lacking, creating a gap in available options for addressing the said aspect,’ said Dr. Jerry K.L. Tan, dermatology specialist and founder of The Healthy Image Centre in Windsor, Ontario. ‘I am delighted that acne patients will soon have a new treatment option.’

WINLEVI may inhibit the effects of androgen receptors in sebaceous gland cells (oil-producing glands in the skin) to help reduce sebum (oil) production and inflammatory cytokines,1, 6, and thus inhibits the androgen cascade.

‘Sun Pharma strives to provide innovative dermatology medicines for Canadians, which fill the gap in necessary treatment options,’ said Abhay Gandhi, Sun Pharma’s North America CEO.

For feedback and suggestions, write to us at [e-mail]